Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Cabozantinib. (23rd March 2016)

• Record Type: Journal Article
• Authors: Nguyen, Linh; Holland, Jaymes; Ramies, David; Mamelok, Richard; Benrimoh, Natacha; Ciric, Sabrina; Marbury, Thomas; Preston, Richard A.; Heuman, Douglas M.; Gavis, Edith; Lacy, Steven
• Is Part Of: Journal of clinical pharmacology. Volume 56:Number 9(2016)
• Page Start: 1130
• Page End: 1140
• Publication Date: 2016-03-23
• Subjects: cabozantinib -- renal impairment -- hepatic impairment -- pharmacokinetics; Pharmacology -- Periodicals; Pharmacology -- Periodicals; Pharmacology, Clinical -- Periodicals; 615.1
• DOI: 10.1002/jcph.714
• Languages: English
• ISSNs: 0091-2700

Abstract

Abstract: Cabozantinib is a tyrosine kinase inhibitor approved for the treatment of patients with progressive, metastatic medullary thyroid cancer. Two clinical pharmacology studies were conducted to characterize single‐dose pharmacokinetics (PK) of cabozantinib in renally or hepatically impaired subjects. Study 1 enrolled 10 subjects, each with mild or moderate impairment of renal function; 12 healthy subjects were matched to the moderate group for age, sex, and body mass index (BMI). Study 2 enrolled 8 males each with mild or moderate hepatic impairment; 10 healthy males were matched to the moderate group for age, BMI, and ethnicity. All subjects received one 60 mg cabozantinib oral capsule dose followed by PK sampling over 21 days. Plasma concentration and protein binding were determined by liquid chromatography tandem mass spectrometry and equilibrium dialysis, respectively. PK parameters were computed using noncompartmental methods. Geometric least squared mean (LSM) ratios for plasma cabozantinib AUC0‐∞ for impaired to normal organ function cohorts were (1) approximately 30% and 6% higher in subjects with mild and moderate renal impairment, respectively, and (2) approximately 81% and 63% higher in subjects with mild and moderate hepatic impairment, respectively. The percentage of unbound drug was slightly higher in both moderately impaired cohorts. No deaths or discontinuations due to adverse events occurred in either study. Cabozantinib should be used with caution in subjects with mild or moderate renal impairment. Subjects with mild or moderate hepatic impairment administered cabozantinib should be monitored closely for potential treatment‐emergent drug toxicity that may necessitate a dose hold or reduction.